J.P. Morgan Maintains Neutral on Thoratec

J.P. Morgan is out with its report today on Thoratec THOR, maintaining Neutral. In a note to clients, J.P. Morgan writes, "Thoratec is the worldwide leader in ventricular assist devices, a market in which the company up until recently has held a near monopoly position. We believe that mechanical circulatory support represents one of the more attractive market opportunities in the cardiovascular space over the next decade. And with an established leadership position in the field, strong physician relationships, and broad pipeline, we believe Thoratec is well positioned to participate in that growth." Shares of THOR closed Friday at $36.10.